Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05004688
Other study ID # 2021P002577
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date March 25, 2022
Est. completion date October 1, 2023

Study information

Verified date February 2023
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study of the effects of Bacillus Calmette-Guérin (BCG) immunization on cerebrospinal fluid and blood-based biomarkers in older with mild cognitive impairment and mild-to-moderate to Alzheimer's disease.


Description:

This single-site, open-label trial will investigate the effects of BCG vaccination on IIR and AD biofluid biomarkers, magnetic resonance imaging (MRI) biomarkers, and neurocognitive/behavioral functioning over a one year period in older adults with mild cognitive impairment (MCI) to mild-to-moderate dementia due to AD. This study will also gather data on tolerability and safety.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date October 1, 2023
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender All
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: 1. Individuals between the ages of 55-85; 2. MCI or moderate dementia due to AD as defined by the 2011 NIA-AA Workgroup recommendations; 3. MoCA = 8 at screening; 4. Global CDR between 0.5-2 (inclusive) at screening; 5. Amyloid and/or tau biomarkers indicative of AD pathology; 6. Education level, English language skills and literacy indicates subject will be able to complete all assessments; 7. Has a study partner who, in the investigator's judgement, has frequent, direct contact with the participant at least several days a week, can accompany the participant to all visits, and is also able to provide information to study investigator/staff; 8. Willing and able to complete all assessment and study procedures, including blood and lumbar punctures, and clinical assessments; 9. If on cholinesterase inhibitor and/or memantine, doses are stable for 3 months prior to baseline; 10. Negative test results for HIV antibody and Tuberculosis (QuantiFERON) at screening; 11. No prior BCG exposure either through birth vaccinations (born in North American) or BCG bladder cancer treatment. Exclusion Criteria: 1. History of chronic infectious disease, such as HIV or untreated or active hepatitis; 2. History of tuberculosis, positive interferon-gamma release assay (IGRA, also known as the QuantiFERON-TB test), including a test with a high reactivity to mycobacteria of non-tuberculosis variety; 3. Prior BCG vaccination, positive T-spot tuberculosis test or a T-spot test showing significant Mycobacteria exposure; 4. A positive SARS-CoV-2 PCR result within 3 months of screening, or known close contact with a confirmed COVID-19 positive person or symptoms highly suspicious for COVID-19 (per CDC guidelines) within 1 month of screening, including fever, cough, shortness of breath, chills, muscle pain, new loss of taste or smell, vomiting or diarrhea, and/or sore throat, based on clinician's judgment; 5. History of treatment with metformin within the past one year; 6. Treatment with other investigational agents which, at the discretion of the investigator, interfere with safety and/or study outcomes; 7. Current treatment with immunosuppressants (calcineurin inhibitors, corticosteroids, or biological or cytotoxic immunosuppressants, or disease or condition likely to require high dose steroid or immunosuppressive therapy); 8. Other conditions or treatments associated with increased risk of infections or treatment with immunosuppressive medications for any reason; 9. Current treatment with aspirin > 160 mg/day or chronic, daily NSAIDs; 10. Current (as of time of study screening) or chronic use of antibiotics; 11. History of keloid formation; 12. Living with someone who is immunosuppressed and/or at high risk for infectious diseases (for example, HIV+ or taking immunosuppressive medications for any reason), or in a job (e.g. healthcare) in which the subject works with immunosuppressed populations; 13. Other/confounding neurological or psychiatric condition, unstable medical or psychiatric conditions, contraindications to BCG use and lab abnormalities or concurrent medication use posing risk for BCG or study procedures; 14. Laboratory abnormalities in B12, Folate, TSH, or other common laboratory parameters that may contribute to cognitive dysfunction per clinician judgment; 15. Laboratory abnormalities in CBC, electrolytes, LFTs, BUN, Cr, total serum immunoglobulins, ESR, CRP, or urinalysis posing risk to treatment with BCG per clinician judgment; 16. Laboratory abnormalities in PT-INR, which would pose a risk to performing the lumbar puncture procedure; 17. Discontinuation of cholinesterase inhibitor or memantine within one month (28 days) prior to baseline visit; 18. Females who are pregnant, lactating or of child-bearing potential; 19. If male with female partner(s) of childbearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol. 20. Administration of live vaccine within 30 days of screening visit or BCG immunizations 21. Administration of non-live vaccine within 14 days of screening visit or BCG immunizations 22. If participating in optional MRI: Existing contraindication to MRI per MGH Athinoula A. Martinos Center research guidelines

Study Design


Intervention

Biological:
Biological/Vaccine: Bacillus Calmette-Guerin (BCG)
Two Bacillus Calmette-Guérin (Japan BCG) vaccine injections spaced four week apart. Each injection will have 0.36-3.9 x 10^6 colony forming units (CFU) reconstituted in 0.1 mL saline.

Locations

Country Name City State
United States Alzheimer's Clinical and Translational Research Unit Charlestown Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Steven E Arnold, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood biomarkers of pharmacodynamic response- cytokines Change in concentration of circulating cytokines in blood from baseline Day 364
Primary Blood biomarkers of pharmacodynamic response- cytokines Change in concentration of circulating cytokines in blood from baseline Day 84
Primary CSF biomarkers of pharmacodynamic response- cytokines Change in concentration of circulating cytokines in CSF from baseline Day 84
Primary CSF biomarkers of pharmacodynamic response- cytokines Change in concentration of circulating cytokines in CSF from baseline Day 364
Primary Blood biomarkers of AD pathology-ATN Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline Day 364
Primary CSF biomarkers of AD pathology-ATN Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline Day 364
Primary Blood biomarkers of AD pathology-ATN Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in blood from baseline Day 84
Primary CSF biomarkers of AD pathology-ATN Change in concentration of ATN markers of AD pathophysiology (Amyloid-ß42/40, phospho-tau, total tau and neurofilament light protein biomarkers) in CSF from baseline Day 84
Primary Cognitive Measures (RBANS) Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score Day 84
Primary Cognitive Measures (RBANS) Change from baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) score Day 364
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A